Thus, it will be interesting to study the effects of targeting the p55PIK-NF-κB pathway as well as other pathways that regulate KIT expression as potential novel treatments for IMA-resistance in GIST patients. Here, NFKB1 is linked to gastrointestinal stromal tumor.